Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8442962 | European Journal of Cancer | 2014 | 8 Pages |
Abstract
Loss of PR in endometrial cancer is associated with increased proliferation, poor survival, and increases from primary to metastatic lesions. Based on expression profiles, CDK inhibitors may have activity in PR negative tumours, supporting further testing in clinical trials for patients with systemic endometrial cancer dependent on PR status.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ingvild Løberg Tangen, Henrica M.J. Werner, Anna Berg, Mari K. Halle, Kanthida Kusonmano, Jone Trovik, Erling A. Hoivik, Gordon B. Mills, Camilla Krakstad, Helga B. Salvesen,